ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Bemcentinib in combination with pembrolizumab demonstrated clinical efficacy in the stage 1 portion of a phase II trial, which evaluated the combination in patients with non–small cell lung cancer who progressed on prior immune checkpoint inhibition, meeting the primary end point of the study.
Feature:

Coverage from the 2020 ASCO Gastrointestinal Cancers Symposium Learn More >>

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.